89.62
Precedente Chiudi:
$89.14
Aprire:
$88.68
Volume 24 ore:
107.49K
Relative Volume:
0.80
Capitalizzazione di mercato:
$877.13M
Reddito:
-
Utile/perdita netta:
$-14.23M
Rapporto P/E:
-46.21
EPS:
-1.9396
Flusso di cassa netto:
$-9.44M
1 W Prestazione:
+8.29%
1M Prestazione:
+24.47%
6M Prestazione:
+31.72%
1 anno Prestazione:
+176.52%
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Nome
Bright Minds Biosciences Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare DRUG vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences Inc
|
89.62 | 872.43M | 0 | -14.23M | -9.44M | -1.9396 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-08 | Iniziato | BTIG Research | Buy |
| 2025-05-13 | Iniziato | TD Cowen | Buy |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-01-23 | Iniziato | Piper Sandler | Overweight |
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-01-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-26 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Bright Minds Biosciences Inc Borsa (DRUG) Ultime notizie
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Sees Significant Growth in Short Interest - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from Analysts at Jefferies Financial Group - MarketBeat
Jefferies initiates Bright Minds stock with buy on epilepsy drug By Investing.com - Investing.com South Africa
Jefferies initiates Bright Minds stock with buy on epilepsy drug - Investing.com
Total debt per share of Bright Minds Biosciences Inc. – NEO:DRUG - TradingView
Certain RSUs of Bright Minds Biosciences Inc. are subject to a Lock-Up Agreement Ending on 8-APR-2026. - marketscreener.com
Certain Options of Bright Minds Biosciences Inc. are subject to a Lock-Up Agreement Ending on 8-APR-2026. - marketscreener.com
7,787,161 Common Shares of Bright Minds Biosciences Inc. are subject to a Lock-Up Agreement Ending on 8-APR-2026. - marketscreener.com
Bright Minds Biosciences (NASDAQ:DRUG) Shares Gap UpHere's Why - MarketBeat
Pullback Watch: Is Bright Minds Biosciences Inc a cyclical or defensive stockRecession Risk & Target Return Focused Stock Picks - baoquankhu1.vn
Bright Minds Biosciences (NASDAQ:DRUG) Trading 7.4% HigherWhat's Next? - MarketBeat
Sentiment Watch: What is PROVs 5 year growth outlookWeekly Profit Recap & Proven Capital Preservation Methods - baoquankhu1.vn
Responsive Playbooks and the DRUG Inflection - Stock Traders Daily
Bright Minds announces ATM offering up to $100 million - MSN
Bright Minds Biosciences Inc. (DRUG.NE) interactive stock chart - Yahoo Finance UK
Bright Minds Biosciences Inc. (DRUG.NE) Stock Forum & Discussion - Yahoo! Finance Canada
Bright Minds Biosciences Inc Live Share Prices and Trades. DRUG.US Live Streaming Share Prices. - London South East
Swing Trade: Whats the profit margin of WB PRCCLTrade Exit Report & Community Verified Watchlist Alerts - baoquankhu1.vn
Bright Minds Biosciences (NASDAQ:DRUG) Given Buy Rating at BTIG Research - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from BTIG Research - MarketBeat
BTIG reiterates Bright Minds Biosciences stock rating on seizure treatment potential - Investing.com India
What is the probability of success for Bright Minds Biosciences Inc (DRUG)’s lead drug candidate? - msn.com
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of “Moderate Buy” from Brokerages - defenseworld.net
Hedge Fund Bets: How much upside does Bright Minds Biosciences Inc have2026 Macro Moves & Weekly Top Stock Performers List - baoquankhu1.vn
What Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate? - insidermonkey.com
Understanding the Setup: (DRUG) and Scalable Risk - Stock Traders Daily
Bright Minds Biosciences (NASDAQ:DRUG) Raised to "Hold" at Wall Street Zen - MarketBeat
Risk Off: Is PMTPRC showing insider buying2026 Decliners & Trade Opportunity Analysis Reports - baoquankhu1.vn
Pullback Watch: Is Bright Minds Biosciences Inc undervalued by DCF analysis2026 Price Momentum & Expert Approved Momentum Ideas - baoquankhu1.vn
303,685 Shares in Bright Minds Biosciences Inc. $DRUG Acquired by Braidwell LP - MarketBeat
The Technical Signals Behind (DRUG) That Institutions Follow - Stock Traders Daily
Bright Minds gains on mid-stage trial win for lead asset - MSN
Is Bright Minds Biosciences Inc. stock supported by innovation pipelineAnalyst Upgrade & Low Risk High Reward Ideas - Naître et grandir
Risk Report: Is Bright Minds Biosciences Inc a cyclical or defensive stock2025 Retail Activity & Daily Volume Surge Signals - baoquankhu1.vn
Bright Minds Biosciences sets January 6 webcast for BMB-101 phase 2 topline results in drug-resistant absence seizures - MSN
Market Outlook: What is the Moat Score of Bright Minds Biosciences IncJuly 2025 Breakouts & Fast Moving Stock Trade Plans - baoquankhu1.vn
HC Wainwright Has Bullish Forecast for DRUG Q2 Earnings - MarketBeat
HC Wainwright Raises Bright Minds Biosciences (NASDAQ:DRUG) Price Target to $145.00 - Defense World
Bright Minds stock price target raised to $145 by H.C. Wainwright on trial data - Investing.com
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
DRUG: HC Wainwright & Co. Raises Price Target to $145, Maintains Buy Rating | DRUG Stock News - GuruFocus
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Precision Trading with Bright Minds Biosciences Inc. (DRUG) Risk Zones - Stock Traders Daily
Bright Minds Biosciences (NASDAQ:DRUG) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
DRUG Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bright Minds Biosciences to Present at Upcoming Conferences - The Manila Times
Published on: 2026-02-24 23:01:51 - baoquankhu1.vn
Stock Report: What are Bright Minds Biosciences Incs recent SEC filings showingJuly 2025 Chart Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
Baird lowers Bright Minds Biosciences Inc. (DRUG) price target to $126, maintains outperform rating ahead of upcoming trials - MSN
Technical Reactions to DRUG Trends in Macro Strategies - Stock Traders Daily
Bright Minds Biosciences Inc Azioni (DRUG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):